287 related articles for article (PubMed ID: 32953229)
1. Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema.
Levy D; Caballero T; Hussain I; Reshef A; Anderson J; Baker J; Schwartz LB; Cicardi M; Prusty S; Feuersenger H; Pragst I; Manning ME
Pediatr Allergy Immunol Pulmonol; 2020 Sep; 33(3):136-141. PubMed ID: 32953229
[No Abstract] [Full Text] [Related]
2. Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management.
West JB; Poarch K; Lumry WR
Clin Ther; 2021 Dec; 43(12):2154-2166.e1. PubMed ID: 34879971
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.
Craig T; Zuraw B; Longhurst H; Cicardi M; Bork K; Grattan C; Katelaris C; Sussman G; Keith PK; Yang W; Hébert J; Hanzlikova J; Staubach-Renz P; Martinez-Saguer I; Magerl M; Aygören-Pürsün E; Farkas H; Reshef A; Kivity S; Neri S; Crisan I; Caballero T; Baeza ML; Hernandez MD; Li H; Lumry W; Bernstein JA; Hussain I; Anderson J; Schwartz LB; Jacobs J; Manning M; Levy D; Riedl M; Christiansen S; Feuersenger H; Pragst I; Mycroft S; Pawaskar D; Jacobs I;
J Allergy Clin Immunol Pract; 2019; 7(6):1793-1802.e2. PubMed ID: 30772477
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema.
Craig T; Feuersenger H; Pragst I; Dang J
Allergy Asthma Proc; 2022 May; 43(3):202-208. PubMed ID: 35524357
[No Abstract] [Full Text] [Related]
5. Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial.
Levy DS; Farkas H; Riedl MA; Hsu FI; Brooks JP; Cicardi M; Feuersenger H; Pragst I; Reshef A
Allergy Asthma Clin Immunol; 2020; 16():8. PubMed ID: 32042283
[TBL] [Abstract][Full Text] [Related]
6. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
[TBL] [Abstract][Full Text] [Related]
7. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate.
Zuraw BL; Cicardi M; Longhurst HJ; Bernstein JA; Li HH; Magerl M; Martinez-Saguer I; Rehman SM; Staubach P; Feuersenger H; Parasrampuria R; Sidhu J; Edelman J; Craig T
Allergy; 2015 Oct; 70(10):1319-28. PubMed ID: 26016741
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial.
Li HH; Mycroft S; Christiansen S; Wood DN; Feuersenger H; Pawaskar D; Jacobs I
Allergy Asthma Proc; 2018 Sep; 39(5):365-370. PubMed ID: 30107868
[TBL] [Abstract][Full Text] [Related]
9. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema.
Bernstein JA; Schwartz L; Yang W; Baker J; Anderson J; Farkas H; Aygören-Pürsün E; Bygum A; Jacobs I; Feuersenger H; Pragst I; Riedl MA
Ann Allergy Asthma Immunol; 2020 Sep; 125(3):334-340.e1. PubMed ID: 32445670
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema.
Zuraw BL; Kalfus I
Am J Med; 2012 Sep; 125(9):938.e1-7. PubMed ID: 22800873
[TBL] [Abstract][Full Text] [Related]
12. Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial.
Riedl MA; Hurewitz DS; Levy R; Busse PJ; Fitts D; Kalfus I
Ann Allergy Asthma Immunol; 2012 Jan; 108(1):49-53. PubMed ID: 22192966
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema.
Pawaskar D; Tortorici MA; Zuraw B; Craig T; Cicardi M; Longhurst H; Li HH; Lumry WR; Martinez-Saguer I; Jacobs J; Bernstein JA; Riedl MA; Katelaris CH; Keith PK; Feussner A; Sidhu J
Clin Exp Allergy; 2018 Oct; 48(10):1325-1332. PubMed ID: 29998524
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy and safety of home treatment with the recombinant human C1-inhibitor in hereditary angioedema resulting from C1-inhibitor deficiency.
Andrási N; Veszeli N; Holdonner Á; Temesszentandrási G; Kőhalmi KV; Varga L; Farkas H
Int Immunopharmacol; 2020 Mar; 80():106216. PubMed ID: 31982824
[TBL] [Abstract][Full Text] [Related]
15. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.
Longhurst H; Cicardi M; Craig T; Bork K; Grattan C; Baker J; Li HH; Reshef A; Bonner J; Bernstein JA; Anderson J; Lumry WR; Farkas H; Katelaris CH; Sussman GL; Jacobs J; Riedl M; Manning ME; Hebert J; Keith PK; Kivity S; Neri S; Levy DS; Baeza ML; Nathan R; Schwartz LB; Caballero T; Yang W; Crisan I; Hernandez MD; Hussain I; Tarzi M; Ritchie B; Králíčková P; Guilarte M; Rehman SM; Banerji A; Gower RG; Bensen-Kennedy D; Edelman J; Feuersenger H; Lawo JP; Machnig T; Pawaskar D; Pragst I; Zuraw BL;
N Engl J Med; 2017 Mar; 376(12):1131-1140. PubMed ID: 28328347
[TBL] [Abstract][Full Text] [Related]
16. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema.
Riedl MA; Lumry WR; Li HH; Banerji A; Bernstein JA; Ba M; Bjrkander J; Magerl M; Maurer M; Rockich K; Chen H; Schranz J
Allergy Asthma Proc; 2016 Nov; 37(6):489-500. PubMed ID: 27931305
[TBL] [Abstract][Full Text] [Related]
18. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.
Craig TJ; Bewtra AK; Hurewitz D; Levy R; Janss G; Jacobson KW; Packer F; Bernstein JA; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
Allergy Asthma Proc; 2012; 33(4):354-61. PubMed ID: 22856636
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
Fukuda T; Yamagami K; Kawahata K; Suzuki Y; Sasaki Y; Miyagi T; Jacobs I; Lawo JP; Glassman F; Akama H; Hide M; Ohsawa I
Allergol Int; 2023 Jul; 72(3):451-457. PubMed ID: 36858856
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy.
Tourangeau LM; Castaldo AJ; Davis DK; Koziol J; Christiansen SC; Zuraw BL
Int Arch Allergy Immunol; 2012; 157(4):417-24. PubMed ID: 22123229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
